Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Core Insights - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, which are custom-built protein drugs designed to address medical challenges that other drug modalities cannot effectively tackle [5] Group 1: Upcoming Conferences - The company will present its latest developments and outlook for 2025 at two investor conferences in January [1] - The first conference is the Baader Helvea Swiss Equities Conference, scheduled for January 8-10 in Bad Ragaz, Switzerland, where COO Alexander Zürcher will present on January 8 [2] - The second conference is the 43rd Annual JP Morgan Healthcare Conference, taking place from January 13-16 in San Francisco, CA, where CEO Patrick Amstutz will present on January 15 at 9:00 am PT [3] Group 2: Company Overview - Molecular Partners AG was founded in 2004 and has offices in Zurich, Switzerland, and Concord, Massachusetts, USA [5] - The company specializes in oncology and has various programs in different stages of pre-clinical and clinical development [5] - Molecular Partners leverages the advantages of DARPins to provide unique solutions through proprietary programs and partnerships with leading pharmaceutical companies [5]